AIM ImmunoTech (FRA:HXB2) Interest Expense : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AIM ImmunoTech's interest expense for the three months ended in Dec. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AIM ImmunoTech's Operating Income for the three months ended in Dec. 2023 was € -12.84 Mil. AIM ImmunoTech's Interest Expense for the three months ended in Dec. 2023 was € 0.00 Mil. GuruFocus does not calculate AIM ImmunoTech's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AIM ImmunoTech Interest Expense Historical Data

The historical data trend for AIM ImmunoTech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Interest Expense Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.38

-0.55

-0.06

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

AIM ImmunoTech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

AIM ImmunoTech (FRA:HXB2) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AIM ImmunoTech's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-12.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €0.45 Mil.

AIM ImmunoTech's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate AIM ImmunoTech's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. AIM ImmunoTech Inc has enough cash to cover all of its debt. Its financial situation is stable.

AIM ImmunoTech (FRA:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (FRA:HXB2) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AIM:USA

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (FRA:HXB2) Headlines

No Headlines